A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-01-06
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety of administering rituximab at a more rapid
infusion rate in patients with moderate to severe rheumatoid arthritis who have had an
inadequate response to biopharmaceuticals that treat diseases by interfering with tumor
necrosis factor (anti-TNF therapies), and were receiving methotrexate therapy for more than
eight weeks.